PTO/SR/21 (09-04)

## RECEIVED CENTRAL FAX CENTER

JUL 08 2005

U death Bereind But it is a second	U.S. P	Approved for use through 07/31/2006, OMB 0651-0031 atent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Patienwork Reduction Act of 1995.	Application Number	action of Information unless it displays a valid QMB control number.
TRANSMITTAL	Filing Date	January 21, 2004
FORM	First Named Inventor	Michel TABART et al.
	Art Unit	1626
(to be used for all correspondence after imital	Examiner Name	STOCKTON, Laura Lynne
	20 Attorney Docker Number	ST01021 US CNT
ENCLOSURES (Check all that apply)  After Allowance Communication to TC		
Fee Transmittal Form	Drawing(s)	And Allowards Communication to 10
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment/Repty	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a Provisional Application	Proprietary Information
	Power of Attorney, Revocation	
Affidavits/declaration(s)	Change of Correspondence Au Terminal Disclaimer	Other Enclosure(s) (please Identify
Extension of Time Request	<b>=</b>	betow):
Express Abandonment Request	Request for Refund	
Information Disclosure Statement	CD, Number of CD(s)	
	Landscape Table on CD	
Certifled Copy of Priority Document(s)	Remarks	
Reply to Missing Parts/		
Incomplete Application Reply to Missing Parts		
under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
AVENTIS PHARMACEUTICALS INC.		
Signature Dalassim Guya-		
Printed name Balarom Gupta		
Date July 8	2005	eg. No. 40,009
9		
CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO, 703-872-9306; Total No. of Pages Transmitted:20)		
Signature Brief Part Litt		
Typed or printed name Brian Pritchett	THE V	Date July 8,2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Three will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the CNet Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NO. 6667 P. 2

1111 0 8 2005

## **PATENT**

Docket No.: ST01021 US CNT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Michel Tabart

Examiner:

Stockton, Laura

Michel Tabart

Serial No.: 10/761,982

Art Unit:

1626

Filed:

January 21, 2004

TELEFAX CERTIFICATE

Title:

Indazole or indole derivatives, and use

thereof in human medicine and more

particularly in oncology

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, at (703) 872-9306 on

Date of Treasmission

Mail Stop: Amendment Commissioner for Patents

P.O. Box 1450

Arlington, VA 22313-1450

## AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY PURSUANT TO 37 C.F.R. § 1.111

Sir:

This is a Rule 111 Amendment in the above-identified patent application in response to the Office Action, paper no. 0305, dated, April 8, 2005, having a response due by July 8, 2005. It is respectfully requested that the following amendments and remarks be entered in this case.

Amendments to claims start on page 2.

Remarks to amendments and the outstanding office action begin on page 17.

ST01021 US CNT

-1 of 19-